A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49

Cancer Biology and Therapy

Volumn 10, Issue 8, 2010, Pages 767-774

  Liu, Guozheng ^a   Dou, Shuping ^a   Baker, Stephen ^a   Akalin, Ali ^a   Cheng, Dengfeng ^a   Chen, Ling ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Pretargeting; Radiotherapy; Rhenium 188; Tumor growth inhibition; Tumor image; Tumor remission

Indexed keywords

18 MER PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER TAG 72 CC49 ANTIBODY; ANTINEOPLASTIC AGENT; COMPLIMENTARY 18 MER PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER RHENIUM 18; TRACER; UNCLASSIFIED DRUG; B72.3 ANTIBODY; CANCER ANTIBODY; MORPHOLINE DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSE INCREASE; HISTOPATHOLOGY; ISOTOPE LABELING; KIDNEY; MOLECULARLY TARGETED THERAPY; MOUSE; MUSCLE; NONHUMAN; RADIATION DOSE; RADIOACTIVITY; RADIOISOTOPE DECAY; TISSUE DISTRIBUTION; TUMOR LOCALIZATION; TUMOR REGRESSION; ANIMAL; CHEMISTRY; COLON TUMOR; DRUG SCREENING; HUMAN; LIVER; LUNG; METABOLISM; METHODOLOGY; PATHOLOGY; RADIATION EXPOSURE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; AREA UNDER CURVE; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; KIDNEY; LIVER; LUNG; MICE; MORPHOLINES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RHENIUM; SPLEEN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78049302551     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.8.12879     Document Type: Article

References (33)

1. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005; 11:7879-85.
2. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005; 11:1250-5.
3. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, at al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003; 101:2340-8.
4. Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, et al. Comparison of immunoscintigraphy, efficacy and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003; 44:437-45.
5. Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996; 37:967-71.
6. 99mTc-labeled morpholino, a DNA analog. J Nucl Med 2002; 43:384-91.
7. 99mTc-morpholinos in mice. Q J Nucl Med 2002; 46:233-43.
8. Liu G, Liu C, Zhang S, He J, Liu N, Gupta S, et al. Investigations of Technetium-99m Morpholino Pretargeting in Mice. Nucl Med Commun 2003; 24:697-705.
9. Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004; 31:417-24. (Pubitemid 38314087)
10. 188Re radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analog. Clin Can Res 2006; 12:4958-64.
11. Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther 2008; 7:1025-32.
12. Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, et al. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging 2009; Epub ahead of print.
13. 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 2005; 46:121-9.
14. Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 2006; 21:117-29.
15. García-Garayoa E, Bläuenstein P, Blanc A, Maes V, Tourwé D, Schubiger PA. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2009; 36:37-47.
16. Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med 1998; 39:34-42.
17. Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 2006; 21:117-29.
18. 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 2008; 7:1116-27.
19. Jia ZY, Deng HF, Pu MF, Luo SZ. Rhenium-188 labelled meso-tetrakis[3,4- bis(carboxymethyleneoxy) phenyl] porphyrin for targeted radiotherapy: preliminary biological evaluation in mice. Eur J Nucl Med Mol Imaging 2008; 35:734-42.
20. Zamora PO, Bender H, Gulhke S, Marek MJ, Knapp FF Jr, Rhodes BA, et al. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res 1997; 17:1803-8.
21. 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J Nucl Med 2001; 42:146-53.
22. 188Re-labeled peptide. Bioconjug Chem 2000; 11:842-54.
23. 188Re. Clin Cancer Res 2003; 9:3880-5.
24. He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem 2007; 18:983-8. (Pubitemid 47010822)
25. 188Re at high labeling efficiency and specific radioactivity. Appl Radiat Isot 2006; 64:971-8.
26. Liu G. Hnatowich DJ. A semiempirical model of tumor pretargeting. Bioconjug Chem 2008; 19:2095-104.
27. Lubic SP, Goodwin DA, Meares CF, Song C, Osen M, Hays M. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma. J Nucl Med 2001; 42:670-78.
28. Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer 2009; 45:3098-103.
29. Moshakis V, McIlhinney RAJ, Raghaven D, Neville AM. Localization of human tumour xenografts after i.v. administration of radiolabelled monoclonal antibodies. Br J Cancer 1981; 44:91-9.
30. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50:1039-42.
31. Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003; 9:3897-913.
32. Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 2007; 34:237-46.
33. Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice-establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging 2005; 32:1115-23.